Clinical Trials /

Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma

NCT02821507

Description:

Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is poor. New treatment options being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR) inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma treated with mTOR inhibitors have been conducted and they show promising results. From these studies the investigators can conclude that the combination of an mTOR inhibitor with cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according to a common protocol with the combination of sirolimus and cyclophosphamide using the growth modulation index for evaluation in the current clinical study protocol.

Related Conditions:
  • Chondrosarcoma
  • Myxoid Liposarcoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
  • Official Title: A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma

Clinical Trial IDs

  • ORG STUDY ID: COSYMO
  • NCT ID: NCT02821507

Conditions

  • Conventional Chondrosarcoma
  • Myxoid Liposarcoma
  • Mesenchymal Chondrosarcoma
  • Dedifferentiated Chondrosarcoma

Interventions

DrugSynonymsArms
sirolimus and cyclophosphamidesirolimus and cyclophosphamide

Purpose

Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is poor. New treatment options being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR) inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma treated with mTOR inhibitors have been conducted and they show promising results. From these studies the investigators can conclude that the combination of an mTOR inhibitor with cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according to a common protocol with the combination of sirolimus and cyclophosphamide using the growth modulation index for evaluation in the current clinical study protocol.

Trial Arms

NameTypeDescriptionInterventions
sirolimus and cyclophosphamideExperimentalcombining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
  • sirolimus and cyclophosphamide

Eligibility Criteria

        Inclusion Criteria:

          -  Pathologically proven conventional chondrosarcoma

          -  Or pathologically proven myxoid liposarcoma with PIK3CA mutation or Phosphatase and
             tensin homolog (PTEN) loss

          -  Or pathologically proven mesenchymal or dedifferentiated chondrosarcoma

          -  Patient is 18 years and up

          -  Documented radiographic progression of disease according to RECIST 1.1 criteria in
             last 6 months

          -  Written signed informed consent

          -  Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x
             109/L, platelets ≥ 80 x 109/L)

          -  Availability of archival tumor material for central review or be able to perform a 3
             core fresh biopsy

          -  Ability to adhere to the study visits and all protocol requirements

        Exclusion Criteria:

          -  Previously treated with an mTOR inhibitor

          -  Known to be allergic to cyclophosphamide

          -  Life expectancy of less than 3 months

          -  No measurable lesions according to RECIST 1.1

          -  Eastern cooperative oncology group (ECOG) Performance status >2

          -  Major surgery less than 4 weeks prior to start of treatment

          -  Known human immunodeficiency virus (HIV) positivity

          -  A decreased renal function with calculated glomerular filtration rate (GFR) < 30ml/min

          -  Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or
             radiotherapy to a target lesion within 21 days prior to the first dose of study drug

          -  Pregnant or lactating women

          -  Other invasive malignancies diagnosed within the last 5 years, except non-melanoma
             skin cancer and localised cured prostate and cervical cancer
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide
Time Frame:16 weeks
Safety Issue:
Description:

Secondary Outcome Measures

Measure:Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations.
Time Frame:8 weeks
Safety Issue:
Description:
Measure:Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma
Time Frame:every 8 weeks until progression (average of 1 year)
Safety Issue:
Description:
Measure:To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1
Time Frame:every 8 weeks until progression (average of 1 year)
Safety Issue:
Description:
Measure:Using the growth modulation index (GMI) to evaluate treatment efficiency
Time Frame:every 8 weeks until progression (average of 1 year)
Safety Issue:
Description:GMI: Time to progression during sirolimus/cyclophosphamide treatment (TTP2) divided by time to progression before start of this treatment TTP1
Measure:The overall survival after start of treatment till death
Time Frame:every 8 weeks until progression (average of 1 year)
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Leiden University Medical Center

Last Updated

February 24, 2020